Effects of AMN107 on characteristics of TEL-PDGFRβ- and FIP1L1-PDGFRα-induced myeloproliferative disease
. | TEL-PDGFRβ Placebo . | TEL-PDGFRβ AMN107 . | FIP1L1-PDGFRα Placebo . | FIP1L1-PDGFRα AMN107 . |
|---|---|---|---|---|
| WBC, × 109/L | ||||
| Mean | 563.7 | 18.6 | 569.7 | 5.6 |
| Standard deviation | 96.0 | 8.8 | 88.2 | 2.3 |
| Median | 583.4 | 15.9 | 613.2 | 4.7 |
| Range | 459.3–648.3 | 10.9–33.5 | 452.8–659.2 | 4.0–9.6 |
| n | 3 | 5 | 5 | 5 |
| Spleen weight, mg | ||||
| Mean | 802.5 | 350.0 | 731.8 | 88.0 |
| Standard deviation | 214.8 | 89.0 | 120.0 | 21.7 |
| Median | 800 | 340 | 700 | 100 |
| Range | 380–1130 | 250–470 | 575–880 | 50–100 |
| n | 8 | 8 | 5 | 5 |
| Liver weight, mg | ||||
| Mean | 1746.3 | 1492.5 | 1666.4 | 1128.0 |
| Standard deviation | 546.9 | 103.3 | 135.5 | 90.9 |
| Median | 1910 | 1535 | 1596 | 1090 |
| Range | 590–2410 | 1320–1590 | 1550–1830 | 1080–1290 |
| n | 8 | 8 | 5 | 5 |
. | TEL-PDGFRβ Placebo . | TEL-PDGFRβ AMN107 . | FIP1L1-PDGFRα Placebo . | FIP1L1-PDGFRα AMN107 . |
|---|---|---|---|---|
| WBC, × 109/L | ||||
| Mean | 563.7 | 18.6 | 569.7 | 5.6 |
| Standard deviation | 96.0 | 8.8 | 88.2 | 2.3 |
| Median | 583.4 | 15.9 | 613.2 | 4.7 |
| Range | 459.3–648.3 | 10.9–33.5 | 452.8–659.2 | 4.0–9.6 |
| n | 3 | 5 | 5 | 5 |
| Spleen weight, mg | ||||
| Mean | 802.5 | 350.0 | 731.8 | 88.0 |
| Standard deviation | 214.8 | 89.0 | 120.0 | 21.7 |
| Median | 800 | 340 | 700 | 100 |
| Range | 380–1130 | 250–470 | 575–880 | 50–100 |
| n | 8 | 8 | 5 | 5 |
| Liver weight, mg | ||||
| Mean | 1746.3 | 1492.5 | 1666.4 | 1128.0 |
| Standard deviation | 546.9 | 103.3 | 135.5 | 90.9 |
| Median | 1910 | 1535 | 1596 | 1090 |
| Range | 590–2410 | 1320–1590 | 1550–1830 | 1080–1290 |
| n | 8 | 8 | 5 | 5 |